Dimitrios Chondros, Chief Medical Officer

Dr. Dimitrios Chondros is Chief Medical Officer and leads the development of Halozyme’s investigational oncology drug, PEGPH20 and its companion diagnostic assay. Dr. Chondros also oversees translational research efforts to advance understanding of Halozyme’s innovative approach to enzymatically modify the tumor microenvironment. He has broad experience directing complex clinical development and companion diagnostic programs toward global regulatory approvals and preparing for market entry. He joined Halozyme in 2015 as Vice President of Clinical Development, responsible for clinical studies of PEGPH20, including the HALO-301 Phase 3 study in metastatic pancreatic cancer patients.

Dr. Chondros joined Halozyme from Genentech where he held positions of increasing responsibilities in the Product Development Oncology division. He was a member of the Antiangiogenesis and Oncology Signaling Franchise Leadership Teams. As Global Development Team Leader he managed physicians and scientists across global sites as well as cross-functional development teams across several key functions, including clinical science, safety, regulatory affairs, biostatistics, research, biomarkers, clinical pharmacology and clinical operations. For Avastin®, Dr. Chondros was accountable for all global development activities in gastrointestinal cancers, including the label for treatment through multiple lines in metastatic colorectal cancer. He began his industry career at Grünenthal followed by Cell Genesys, where he directed the clinical development of an investigational immunotherapy for prostate cancer. Dr. Chondros has worked for the biopharmaceutical industry in Europe, China and USA.

He is a board certified general surgeon with experience as clinical trial investigator in numerous indications. Dr. Chondros studied medicine at the RWTH Aachen University in Germany and received his M.D. from the University of Zürich, Switzerland.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.